Analyst firms · Guggenheim · ACAD
Guggenheim ACAD price target and rating history
ACADIA Pharmaceuticals Inc. (ACAD) · Health Care
Guggenheim rates ACADIA Pharmaceuticals Inc. (ACAD) Neutral with a $20 price target, as of its latest action on Jan 3, 2025. It has published 4 rating actions on ACAD since November 2021, including 2 upgrades and 2 downgrades. Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
- Current rating
- Neutral
- Price target
- $20
- Median target, all firms
- $31
- Actions on ACAD
- 4
Guggenheim price target on ACAD
Every Guggenheim rating on ACAD
- Jan 3, 2025
- Jan 3, 2023
- Dec 21, 2021
- Nov 1, 2021
How other firms rate ACAD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $23 | Oct 13, 2026 |
| BofA Securities | Buy | $29 | Mar 25, 2026 |
| Wolfe Research | Outperform | $33 | Feb 24, 2026 |
| Mizuho | Outperform | $35 | Feb 23, 2026 |
Questions about Guggenheim and ACAD
- What is Guggenheim's price target for ACAD?
- Guggenheim's latest stated price target for ACADIA Pharmaceuticals Inc. (ACAD) is $20, from its action on Jan 3, 2025.
- What is Guggenheim's rating on ACAD?
- Guggenheim rates ACAD Neutral, a neutral rating, as of Jan 3, 2025.
- When did Guggenheim last change its view on ACAD?
- On Jan 3, 2025, Guggenheim downgrades to Neutral from Buy, price target $23 to $20.
- How does Guggenheim's ACAD target compare with other analysts?
- Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
More ACAD rating histories
All Guggenheim ratingsACAD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.